Charalambos Antoniades Selected Research

Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)

3/2012	Systemic and vascular oxidation limits the efficacy of oral tetrahydrobiopterin treatment in patients with coronary artery disease.
12/2011	Gene therapy targeting inflammation in atherosclerosis.
7/2011	Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling.
5/2009	Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis.
7/2008	GCH1 haplotype determines vascular and plasma biopterin availability in coronary artery disease effects on vascular superoxide production and endothelial function.
1/2008	Statins ameliorate atherosclerosis induced by inhibition of nitric oxide synthase: another novel vascular protective mechanism?
12/2007	Altered plasma versus vascular biopterins in human atherosclerosis reveal relationships between endothelial nitric oxide synthase coupling, endothelial function, and inflammation.
3/2007	Effects of endothelial nitric oxide synthase gene polymorphisms on oxidative stress, inflammatory status, and coronary atherosclerosis: an example of a transient phenotype.
9/2005	Genetic polymorphism on endothelial nitric oxide synthase affects endothelial activation and inflammatory response during the acute phase of myocardial infarction.
10/2004	Evidence for association between endothelial nitric oxide synthase gene polymorphism (G894T) and inflammatory markers: the ATTICA study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Charalambos Antoniades Research Topics

Disease

50	Atherosclerosis 06/2022 - 08/2002
44	Inflammation (Inflammations) 10/2022 - 10/2005
34	Coronary Artery Disease (Coronary Atherosclerosis) 01/2022 - 08/2002
26	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 08/2002
22	Heart Failure 12/2021 - 08/2002
18	Myocardial Infarction 01/2021 - 09/2005
12	Hyperemia 06/2009 - 06/2003
10	Obesity 01/2022 - 05/2011
10	Type 2 Diabetes Mellitus (MODY) 10/2015 - 10/2003
9	Thrombosis (Thrombus) 01/2020 - 06/2003
8	Vascular Diseases (Vascular Disease) 01/2020 - 09/2006
7	Insulin Resistance 01/2020 - 01/2009
7	Atherosclerotic Plaque (Atheroma) 01/2017 - 08/2008
6	Hypertension (High Blood Pressure) 10/2022 - 08/2002
6	Diabetes Mellitus 07/2020 - 11/2003
6	Acute Coronary Syndrome 01/2012 - 08/2006
5	Rupture 01/2020 - 08/2006
5	Atrial Fibrillation 04/2016 - 09/2009
5	Hypercholesterolemia 07/2010 - 08/2002
4	Body Weight (Weight, Body) 01/2022 - 06/2008
3	Coronary Disease (Coronary Heart Disease) 01/2022 - 01/2011
3	Cardiomyopathies (Cardiomyopathy) 06/2021 - 04/2004
3	Myocardial Ischemia (Ischemic Heart Diseases) 09/2014 - 04/2004
3	Homocysteinemia 08/2011 - 06/2008
3	Unstable Angina 07/2010 - 01/2006
2	Dyslipidemias (Dyslipidemia) 01/2022 - 07/2020
2	Hypoadiponectinemia 01/2022 - 06/2015
2	Fibrosis (Cirrhosis) 12/2021 - 04/2016
2	COVID-19 06/2021 - 01/2021
2	Heart Diseases (Heart Disease) 06/2021 - 06/2021
2	Hyperglycemia 01/2020 - 01/2009
2	Necrosis 01/2017 - 02/2011
2	Stroke (Strokes) 04/2016 - 01/2009
2	Stable Angina 10/2013 - 04/2006
2	Pathologic Constriction (Stenosis) 04/2012 - 10/2010
2	Infarction (Infarctions) 02/2011 - 11/2008

Drug/Important Bio-Agent (IBA)

30	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 09/2017 - 12/2005
22	Biomarkers (Surrogate Marker)IBA 10/2022 - 01/2008
15	LipidsIBA 10/2022 - 04/2006
15	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2020 - 10/2005
13	CytokinesIBA 11/2021 - 04/2004
12	Interleukin-6 (Interleukin 6)IBA 01/2022 - 10/2003
11	AntioxidantsIBA 11/2017 - 06/2003
10	C-Reactive ProteinIBA 01/2022 - 07/2007
10	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 03/2012 - 10/2004
9	Atorvastatin (Lipitor)FDA Link 07/2011 - 02/2005
8	AdipokinesIBA 11/2021 - 05/2011
8	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2019 - 09/2011
8	oxidized low density lipoproteinIBA 09/2012 - 09/2005
7	CalciumIBA 02/2021 - 12/2006
7	VitaminsIBA 08/2011 - 06/2003
6	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022 - 04/2004
6	Superoxides (Superoxide)IBA 12/2021 - 09/2006
6	Biological ProductsIBA 11/2021 - 01/2017
6	Pharmaceutical PreparationsIBA 06/2021 - 05/2007
6	Proteins (Proteins, Gene)FDA Link 01/2020 - 10/2003
6	AdiponectinIBA 11/2017 - 05/2011
6	HomocysteineIBA 12/2014 - 01/2005
6	sapropterin (tetrahydrobiopterin)FDA Link 03/2012 - 09/2006
6	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2012 - 01/2009
5	EnzymesIBA 01/2022 - 09/2008
5	InterleukinsIBA 01/2019 - 09/2005
5	Nitric Oxide Synthase (NO Synthase)IBA 07/2018 - 09/2006
5	Fibrinogen (Factor I)FDA Link 10/2013 - 07/2007
5	NitratesIBA 06/2009 - 10/2003
5	von Willebrand FactorIBA 04/2009 - 10/2003
5	Simendan (Levosimendan)IBA 02/2009 - 05/2004
4	CholesterolIBA 10/2022 - 02/2005
4	NADPH Oxidases (NAD(P)H oxidase)IBA 01/2019 - 10/2005
4	BiopterinsIBA 03/2012 - 12/2007
4	Matrix Metalloproteinases (MMPs)IBA 01/2012 - 12/2010
4	dimethylarginineIBA 08/2011 - 02/2007
4	Ascorbic Acid (Vitamin C)FDA LinkGeneric 05/2010 - 10/2003
3	Apolipoproteins E (ApoE)IBA 06/2022 - 12/2014
3	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 09/2010
3	Insulin (Novolin)FDA Link 01/2022 - 06/2007
3	Folic Acid (Vitamin M)FDA LinkGeneric 12/2014 - 05/2007
3	LDL Lipoproteins (beta Lipoproteins)IBA 09/2012 - 10/2010
3	Methionine (L-Methionine)FDA Link 08/2011 - 06/2008
3	ThiazolidinedionesIBA 05/2011 - 01/2009
3	CD40 Ligand (CD40L)IBA 07/2010 - 05/2006
3	Arginine (L-Arginine)FDA Link 05/2007 - 08/2002
3	Nitroglycerin (Dynamite)FDA LinkGeneric 02/2006 - 06/2003
2	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 06/2021 - 01/2012
2	AntibodiesIBA 01/2021 - 11/2008
2	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 01/2020 - 01/2017
2	Interleukin-1 (Interleukin 1)IBA 01/2020 - 07/2009
2	N,N-dimethylarginine (asymmetric dimethylarginine)IBA 07/2018 - 09/2015
2	Troponin IIBA 01/2017 - 02/2011
2	VaccinesIBA 09/2014 - 10/2011
2	Endothelin-1 (Endothelin 1)IBA 09/2013 - 05/2010
2	Metalloproteases (Metalloproteinases)IBA 01/2013 - 12/2010
2	NADP (NADPH)IBA 01/2012 - 05/2009
2	GTP Cyclohydrolase (GTP Cyclohydrolase I)IBA 10/2011 - 09/2008
2	Metformin (Glucophage)FDA LinkGeneric 05/2011 - 09/2010
2	Angiotensin Receptor AntagonistsIBA 05/2011 - 01/2009

Therapy/Procedure

10	Therapeutics 01/2021 - 05/2004
9	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 01/2020 - 05/2007
4	Secondary Prevention 02/2021 - 01/2012
4	Stents 01/2020 - 04/2012